Searched for: department:Medicine. General Internal Medicine
recentyears:2
school:SOM
Polio reappears in 9th country [Newspaper Article]
Altman, Lawrence K
Botswana is the ninth previously polio-free country where the crippling disease has reappeared in recent months and the farthest from its presumed source, northern Nigeria. There, officials have stopped polio vaccinations because of religious and political opposition to it, said officials of the WHO, a U.N. agency in Geneva. In the past 18 months, polio viruses genetically linked to northern Nigeria have caused new cases of polio in nine previously polio-free countries. Besides Botswana, they are Benin, Burkina Faso, Cameroon, the Central African Republic, Chad, Ghana, Ivory Coast and Togo
PROQUEST:618193371
ISSN: n/a
CID: 82023
Prolonged hypocalcemia after treatment with zoledronic acid in a patient with prostate cancer and vitamin D deficiency [Letter]
Breen, Tracy L; Shane, Elizabeth
PMID: 15084635
ISSN: 0732-183x
CID: 2589582
Do new protease inhibitors offer improved sequencing options? Issues of PI resistance and sequencing
Hsu, RK; Wainberg, MA
First-generation protease inhibitors (PIs) have yielded clinical benefit, although their use has been accompanied by a high incidence of treatment-emergent resistance as well as the transmission of drug-resistant viruses in acute infection. In addition, mutations in isolates that are resistant to PIs can often confer cross-resistance, jeopardizing class effectiveness. Despite the fact that several PIs display a high genetic barrier to resistance, diminished susceptibility to these drugs can still result from poor adherence, due to poor tolerability, high pill burden, frequent dosing, and complex food and water requirements. Two new PIs, atazanavir (ATV) and fosamprenavir (FPV, or 908), have several potential advantages over first-generation agents with regard to potency, tolerability, and convenience. Clinical trials with these agents suggest a relatively high barrier to resistance, with well-characterized mutational pathways and minimal cross-resistance with other PIs. Therefore, these new agents hold promise as first-line PIs with the added potential for salvageability. In addition, two nonpeptidic PIs in advanced development, tipranavir (TPV) and TMC-114, maintain high potency against isolates resistant to earlier-generation PIs and have each shown usefulness in salvage therapy. Thus, the availability of new PIs that combine favorable resistance profiles with improved tolerability has the potential to lead to a new paradigm of how to better utilize and sequence PIs in antiretroviral therapy. The use of these new PIs may provide improved long-term, durable viral suppression, enhancing not only therapeutic outcomes but also patient quality of life for those living with HIV infection and AIDS
ISI:000220794000003
ISSN: 1525-4135
CID: 141998
H. SHERWOOD LAWRENCE, PIONEER IMMUNOLOGIST, EXPERT ON LYMPHOCYTES [Newspaper Article]
Altman, Lawrence K
Dr. [H. SHERWOOD LAWRENCE], who was known as Jerry, was also an expert in infectious diseases, and his research generated other advances in immunology. Dr. Lawrence conducted research on the way the body rejects transplanted organs and how various conditions can damage tissue. Transfer factor is a small molecule, and it has been the center of scientific mystery, in part because Dr. Lawrence and other scientists were unable to identify it precisely. Some scientists suspect that transfer factor represents bits of many molecules. Dr. Lawrence also identified a link between the way cells respond immunologically to microbes like the bacterium that causes tuberculosis and the type of immune responses involved in the rejection of transplanted organs, said Dr. Fred T. Valentine, an immunologist who worked with Dr. Lawrence at NYU
PROQUEST:616234681
ISSN: 1068-624x
CID: 82024
H. Sherwood Lawrence, 87, Immunology Pioneer [Newspaper Article]
Altman, Lawrence K
Dr. Lawrence, who was known as Jerry, was also an expert in infectious diseases, and his research generated other advances in immunology. Dr. Lawrence conducted research on the way the body rejects transplanted organs and how various conditions can damage tissue. Transfer factor is a small molecule, and it has been the center of scientific mystery, in part because Dr. Lawrence and other scientists were unable to identify it precisely. Some scientists suspect that transfer factor represents bits of many molecules. Dr. Lawrence also identified a link between the way cells respond immunologically to microbes like the bacterium that causes tuberculosis and the type of immune responses involved in the rejection of transplanted organs, said Dr. Fred T. Valentine, an immunologist who worked with Dr. Lawrence at N.Y.U
PROQUEST:611899631
ISSN: 0362-4331
CID: 82025
STUDENTJAMA. The clinical relevance of genomic variation
Kansagra, Susan; List, Justin
PMID: 15069054
ISSN: 0098-7484
CID: 161050
Kerry Has Shoulder Surgery [Newspaper Article]
Wilgoren, Jodi; Altman, Lawrence K
Senator John Kerry's doctor said that he found small tears on two torn tendons during surgery on Mr. Kerry's right shoulder on Wednesday but that the 45-minute procedure was completed without complications and the patient awoke from his time under general anesthesia lucid and laughing. Dr. [Bertram Zarins] said Mr. Kerry would most likely be back in handshaking shape in a couple of weeks and to resume hoisting babies on the rope line shortly after that. Mr. Kerry's habit of tossing footballs with his staff for fun and photo opportunities may have to wait a few months though, he said
PROQUEST:596533501
ISSN: 0362-4331
CID: 82026
Randomized controlled trial of the impact of intensive patient education on compliance with fecal occult blood testing [Meeting Abstract]
Stokamer, C; Tenner, C; Chaudhuri, J; Vazquez, E; Bini, EJ
ISI:000220890200969
ISSN: 0016-5085
CID: 72433
Formulae predict shorter follow-up for early-stage breast cancer
Oransky, Ivan
PMID: 15085838
ISSN: 1470-2045
CID: 70599
Practicing bioterrorism-related psychosocial skills with standardized patients [Meeting Abstract]
Zabar, S; Kalet, AL; Kachur, EK; Triola, M; Yedidia, M; Blaser, M; Steigbigel, NH; Freeman, R; Lipkin, M
ISI:000221125800720
ISSN: 0884-8734
CID: 702212